Florida Gastroenterological Society
Florida Gastroenterological Society

Gilead DAAs safe, effective for adults with HCV, severe renal impairment

The FDA approved changes to the product labels for direct-acting antivirals Harvoni, Epclusa, and Vosevi to include new efficacy and safety data for adults with hepatitis C and severe renal impairment, including those who require dialysis.“The product labeling updates for Epclusa, Harvoni and Vosevi recognize the high unmet need for effective HCV treatments for patients with severe renal impairment, including those with end stage renal disease (ESRD) who are on dialysis,” Gilead said in a statement sent to Healio Gastroenterology and Liver Disease. “People with chronic HCVRead More

Posted in News

FGS Login Portal

Not Member yet? Register | Forgot password?